88 related articles for article (PubMed ID: 9144465)
1. In vivo migration of dendritic cells differentiated in vitro: a chimpanzee model.
Barratt-Boyes SM; Watkins SC; Finn OJ
J Immunol; 1997 May; 158(10):4543-7. PubMed ID: 9144465
[TBL] [Abstract][Full Text] [Related]
2. Splenic dendritic cells pulsed with Ixodes ricinus tick saliva prime naive CD4+T to induce Th2 cell differentiation in vitro and in vivo.
Mejri N; Brossard M
Int Immunol; 2007 Apr; 19(4):535-43. PubMed ID: 17344202
[TBL] [Abstract][Full Text] [Related]
3. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients.
Verdijk P; Aarntzen EH; Lesterhuis WJ; Boullart AC; Kok E; van Rossum MM; Strijk S; Eijckeler F; Bonenkamp JJ; Jacobs JF; Blokx W; Vankrieken JH; Joosten I; Boerman OC; Oyen WJ; Adema G; Punt CJ; Figdor CG; de Vries IJ
Clin Cancer Res; 2009 Apr; 15(7):2531-40. PubMed ID: 19318472
[TBL] [Abstract][Full Text] [Related]
4. Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine-immune cellular network.
Bodey B; Bodey B; Kaiser HE
In Vivo; 1997; 11(4):351-70. PubMed ID: 9292303
[TBL] [Abstract][Full Text] [Related]
5. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage.
Labeur MS; Roters B; Pers B; Mehling A; Luger TA; Schwarz T; Grabbe S
J Immunol; 1999 Jan; 162(1):168-75. PubMed ID: 9886383
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell migration to peripheral lymph nodes.
Martín-Fontecha A; Lanzavecchia A; Sallusto F
Handb Exp Pharmacol; 2009; (188):31-49. PubMed ID: 19031020
[TBL] [Abstract][Full Text] [Related]
7. An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model.
Hunter TB; Alsarraj M; Gladue RP; Bedian V; Antonia SJ
Scand J Immunol; 2007 May; 65(5):479-86. PubMed ID: 17444959
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells matured with TNF can be further activated in vitro and after subcutaneous injection in vivo which converts their tolerogenicity into immunogenicity.
Voigtländer C; Rössner S; Cierpka E; Theiner G; Wiethe C; Menges M; Schuler G; Lutz MB
J Immunother; 2006; 29(4):407-15. PubMed ID: 16799336
[TBL] [Abstract][Full Text] [Related]
9. Cytokines in the generation and maturation of dendritic cells: recent advances.
Zou GM; Tam YK
Eur Cytokine Netw; 2002; 13(2):186-99. PubMed ID: 12101074
[TBL] [Abstract][Full Text] [Related]
10. Antigen presentation by dendritic cells and their significance in antineoplastic immunotherapy.
Bodey B; Siegel SE; Kaiser HE
In Vivo; 2004; 18(1):81-100. PubMed ID: 15011756
[TBL] [Abstract][Full Text] [Related]
11. CD40 is necessary for activation of naïve T cells by a dendritic cell line in vivo but not in vitro.
Haase C; Michelsen BK; Jørgensen TN
Scand J Immunol; 2004 Mar; 59(3):237-45. PubMed ID: 15030573
[TBL] [Abstract][Full Text] [Related]
12. IL-4 deficiency does not impair the ability of dendritic cells to initiate CD4+ and CD8+ T cell responses in vivo.
Roberts JM; Yang J; Ronchese F
Int Immunol; 2004 Oct; 16(10):1451-8. PubMed ID: 15326095
[TBL] [Abstract][Full Text] [Related]
13. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
Xiao BG; Duan RS; Zhu WH; Lu CZ
Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
[TBL] [Abstract][Full Text] [Related]
14. Changes in the motility, morphology, and F-actin architecture of human dendritic cells in an in vitro model of dendritic cell development.
Shutt DC; Daniels KJ; Carolan EJ; Hill AC; Soll DR
Cell Motil Cytoskeleton; 2000 Jul; 46(3):200-21. PubMed ID: 10913967
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells.
Dembic Z; Schenck K; Bogen B
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2697-702. PubMed ID: 10706628
[TBL] [Abstract][Full Text] [Related]
16. Monocyte-derived dendritic cells as antigen-presenting cells in T-cell proliferation and cytokine production.
Sung SS
Methods Mol Med; 2008; 138():97-106. PubMed ID: 18615247
[TBL] [Abstract][Full Text] [Related]
17. Dendritic cells in germ-free and specific pathogen-free mice have similar phenotypes and in vitro antigen presenting function.
Walton KL; He J; Kelsall BL; Sartor RB; Fisher NC
Immunol Lett; 2006 Jan; 102(1):16-24. PubMed ID: 16105690
[TBL] [Abstract][Full Text] [Related]
18. In-vivo impaired T helper 1 cell development in submandibular lymph nodes due to IL-12 deficiency following antigen injection into the anterior chamber of the eye.
Perez VL; Biuckians AJ; Streilein JW
Ocul Immunol Inflamm; 2000 Mar; 8(1):9-24. PubMed ID: 10806431
[TBL] [Abstract][Full Text] [Related]
19. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state.
De Vries IJ; Krooshoop DJ; Scharenborg NM; Lesterhuis WJ; Diepstra JH; Van Muijen GN; Strijk SP; Ruers TJ; Boerman OC; Oyen WJ; Adema GJ; Punt CJ; Figdor CG
Cancer Res; 2003 Jan; 63(1):12-7. PubMed ID: 12517769
[TBL] [Abstract][Full Text] [Related]
20. The presence of GM-CSF and IL-4 interferes with effect of TGF-beta1 on antigen presenting cells in patients with multiple sclerosis and in rats with experimental autoimmune encephalomyelitis.
Xiao BG; Zhu WH; Lu CZ
Cell Immunol; 2007 Sep; 249(1):30-6. PubMed ID: 18061154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
